GB201904337D0 - A delivery system - Google Patents

A delivery system

Info

Publication number
GB201904337D0
GB201904337D0 GBGB1904337.1A GB201904337A GB201904337D0 GB 201904337 D0 GB201904337 D0 GB 201904337D0 GB 201904337 A GB201904337 A GB 201904337A GB 201904337 D0 GB201904337 D0 GB 201904337D0
Authority
GB
United Kingdom
Prior art keywords
delivery system
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1904337.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sisaf Ltd
Original Assignee
Sisaf Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sisaf Ltd filed Critical Sisaf Ltd
Priority to GBGB1904337.1A priority Critical patent/GB201904337D0/en
Publication of GB201904337D0 publication Critical patent/GB201904337D0/en
Priority to CN202080025724.5A priority patent/CN113677332B/zh
Priority to PCT/GB2020/050854 priority patent/WO2020193999A1/en
Priority to US17/598,703 priority patent/US12496278B2/en
Priority to CA3133117A priority patent/CA3133117C/en
Priority to JP2021557827A priority patent/JP7637416B2/ja
Priority to AU2020249810A priority patent/AU2020249810B2/en
Priority to EP20718725.3A priority patent/EP3946280A1/en
Priority to CN202311342050.3A priority patent/CN117398362A/zh
Priority to JP2024158947A priority patent/JP7784754B2/ja
Priority to US19/381,591 priority patent/US20260096997A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
GBGB1904337.1A 2019-03-28 2019-03-28 A delivery system Ceased GB201904337D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB1904337.1A GB201904337D0 (en) 2019-03-28 2019-03-28 A delivery system
CN202311342050.3A CN117398362A (zh) 2019-03-28 2020-03-30 包含硅纳米颗粒的递送系统
CA3133117A CA3133117C (en) 2019-03-28 2020-03-30 A delivery system comprising silicon nanoparticles
PCT/GB2020/050854 WO2020193999A1 (en) 2019-03-28 2020-03-30 A delivery system comprising silicon nanoparticles
US17/598,703 US12496278B2 (en) 2019-03-28 2020-03-30 Delivery system comprising silicon nanoparticles
CN202080025724.5A CN113677332B (zh) 2019-03-28 2020-03-30 包含硅纳米颗粒的递送系统
JP2021557827A JP7637416B2 (ja) 2019-03-28 2020-03-30 ケイ素ナノ粒子を含む送達システム
AU2020249810A AU2020249810B2 (en) 2019-03-28 2020-03-30 A delivery system comprising silicon nanoparticles
EP20718725.3A EP3946280A1 (en) 2019-03-28 2020-03-30 A delivery system comprising silicon nanoparticles
JP2024158947A JP7784754B2 (ja) 2019-03-28 2024-09-13 ケイ素ナノ粒子を含む送達システム
US19/381,591 US20260096997A1 (en) 2019-03-28 2025-11-06 Delivery system comprising silicon nanoparticles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1904337.1A GB201904337D0 (en) 2019-03-28 2019-03-28 A delivery system

Publications (1)

Publication Number Publication Date
GB201904337D0 true GB201904337D0 (en) 2019-05-15

Family

ID=66442849

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1904337.1A Ceased GB201904337D0 (en) 2019-03-28 2019-03-28 A delivery system

Country Status (8)

Country Link
US (2) US12496278B2 (https=)
EP (1) EP3946280A1 (https=)
JP (2) JP7637416B2 (https=)
CN (2) CN117398362A (https=)
AU (1) AU2020249810B2 (https=)
CA (1) CA3133117C (https=)
GB (1) GB201904337D0 (https=)
WO (1) WO2020193999A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022132196A (ja) * 2021-02-26 2022-09-07 ナノ ターゲティング アンド セラピー バイオファーマ インコーポレイテッド 薬剤を後眼部に送達するための方法およびその使用
GB202110645D0 (en) * 2021-07-23 2021-09-08 Sisaf Ltd Protection of biological molecules from degradation
GB202110644D0 (en) * 2021-07-23 2021-09-08 Sisaf Ltd Improved nucleic acid vector particles
GB202110646D0 (en) * 2021-07-23 2021-09-08 Sisaf Ltd Nucleic acid vector compositions
CN121622565A (zh) * 2022-05-16 2026-03-10 苏州维益生物科技有限公司 纳米颗粒、其制备和应用、及包括其的眼疾药物及其制备
GB202210794D0 (en) 2022-07-22 2022-09-07 Sisaf Ltd Lipid formulations
GB202300914D0 (en) * 2023-01-20 2023-03-08 Sisaf Ltd Manufacturing process
GB202300915D0 (en) * 2023-01-20 2023-03-08 Sisaf Ltd mRNA COMPOSITIONS
GB202300911D0 (en) * 2023-01-20 2023-03-08 Sisaf Ltd Therapeutic compositions and methods
GB202300912D0 (en) * 2023-01-20 2023-03-08 Sisaf Ltd Therapeutic compostions and methods
CN116473928B (zh) * 2023-03-01 2024-06-14 东北师范大学 精氨酸/磷酸钙纳米粒子的制备方法及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK175531B1 (da) 1986-12-15 2004-11-22 Nexstar Pharmaceuticals Inc Leveringsvehikel med amphiphil-associeret aktiv bestanddel
NL9400189A (nl) 1994-02-07 1995-09-01 Bio Pharma Sciences Bv Gestabiliseerd orthosiliciumzuur bevattend preparaat, een werkwijze voor het bereiden daarvan en een biologisch preparaat.
CN1227482A (zh) 1996-06-27 1999-09-01 普罗克特和甘保尔公司 化妆品组合物
FR2799758B1 (fr) 1999-10-15 2002-05-17 Exsymol Sa Complexe a base d'acide orthosilicique biologiquement assimilable, se presentant sous forme solide, stable et concentree, et procede de preparation
GB0104383D0 (en) 2001-02-22 2001-04-11 Psimedica Ltd Cancer Treatment
US6670335B2 (en) 2001-03-05 2003-12-30 A. P. Pharma, Inc. Fluorouracil-containing formulation
EP1391426A1 (en) 2002-08-12 2004-02-25 Bio Minerals N.V. Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate
JP2006016390A (ja) 2004-06-04 2006-01-19 Toyo Shinyaku:Kk プロアントシアニジン含有組成物
CN1981044B (zh) * 2004-06-07 2010-05-05 普洛体维生物治疗公司 包封干扰rna的脂质
ES2669585T3 (es) 2004-10-29 2018-05-28 The Regents Of The University Of California Micropartículas porosas de silicio para la entrega de fármaco para el ojo
CN101277704A (zh) * 2005-04-12 2008-10-01 因特拉迪格姆公司 用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
GB0515353D0 (en) 2005-07-27 2005-08-31 Psimedica Ltd Food
US8920821B2 (en) 2006-04-14 2014-12-30 Perrigo Israel Pharmaceuticals Ltd. Pharmaceutical compositions comprising silica microspheres
US7696866B2 (en) 2007-06-28 2010-04-13 Microsoft Corporation Learning and reasoning about the context-sensitive reliability of sensors
KR20160021307A (ko) * 2007-07-10 2016-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법
US20090053268A1 (en) 2007-08-22 2009-02-26 Depablo Juan J Nanoparticle modified lubricants and waxes with enhanced properties
EP2030632A1 (en) 2007-09-03 2009-03-04 UMC Utrecht Holding B.V. A carrier particle for use in bio-applications
GB0817936D0 (en) 2008-09-30 2008-11-05 Intrinsiq Materials Global Ltd Porous materials
IT1394656B1 (it) 2009-07-03 2012-07-05 Brev Angela Srl Processo per la produzione e l'assemblaggio di una siringa per operazioni medicali
GB0913255D0 (en) 2009-07-30 2009-09-02 Sisaf Ltd Topical composition
JP2011032194A (ja) 2009-07-31 2011-02-17 Kracie Home Products Ltd 油中水型乳化化粧料
US8992984B1 (en) 2009-10-21 2015-03-31 Stc.Unm Protocells and their use for targeted delivery of multicomponent cargos to cancer cells
ES2385080B1 (es) * 2010-12-21 2013-05-10 Universidad Del Pais Vasco-Euskal Herriko Unibertsitatea Nanopartículas lipídicas para el tratamiento de enfermedades oculares.
EP2765997A4 (en) 2011-10-14 2015-06-24 Stc Unm POROUS NANOPARTICLE-SUPPORTED LIPID DOUBLE LAYERS (PROTOCOLS) FOR THE TARGETED RELEASE BY TRANSDERMAL RELEASE AND USE METHOD THEREFOR
US9096679B2 (en) * 2012-12-03 2015-08-04 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
EP2968571A4 (en) 2013-03-15 2016-09-07 Psivida Inc BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS
US20170165375A1 (en) 2013-04-02 2017-06-15 Stc. Unm Antibiotic protocells and related pharmaceutical formulations and methods of treatment
JP2016521568A (ja) 2013-06-12 2016-07-25 ユニヴェルシテ・ドゥ・ナミュールＵｎｉｖｅｒｓｉｔｅ ｄｅ Ｎａｍｕｒ 生細胞の冷凍保存
EP3470089A1 (en) * 2013-12-12 2019-04-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
GB201402669D0 (en) 2014-02-14 2014-04-02 Medical Res Council Stabilised silicate compositions and their uses
EP2946793A1 (en) * 2014-05-23 2015-11-25 Universitat Rovira I Virgili Silicon particles targeting tumor cells
CN104127886A (zh) 2014-07-16 2014-11-05 上海理工大学 一种CpG核酸药物输送系统及其制备方法
CN105434205A (zh) 2014-11-08 2016-03-30 马南行 一种眼部快速弹开皱纹延缓衰老的组合物及其制备方法
CN114533898B (zh) * 2015-07-09 2025-07-01 加利福尼亚大学董事会 融合脂质体包被的多孔硅纳米颗粒
LU92784B1 (en) 2015-07-22 2017-01-31 Luxembourg Inst Of Science And Tech (List) Negatively charged self-assembling supported lipid bilayer on mesoporous silica nanoparticles, method of synthesis and use as a nanovector
WO2017040976A1 (en) * 2015-09-02 2017-03-09 Erkki Ruoslahti Compounds and compositions for targeting brain injuries and methods of use thereof
US20180344641A1 (en) 2015-09-04 2018-12-06 C. Jeffrey Brinker Mesoporous silica nanoparticles and supported lipid bi-layer nanoparticles for biomedical applications
US20190262469A1 (en) 2015-09-04 2019-08-29 C. Jeffrey Brinker Protocells to treat microbial infection and for synergistic delivery
JP7384512B2 (ja) * 2015-10-22 2023-11-21 モデルナティエックス インコーポレイテッド 広域インフルエンザウイルスワクチン
EP4218739A3 (en) 2016-01-08 2023-08-09 The Regents of The University of California Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
WO2017181115A1 (en) * 2016-04-14 2017-10-19 Spinnaker Biosciences, Inc. Porous silicon materials comprising a metal silicate for delivery of therapeutic agents
CN106177982A (zh) 2016-07-26 2016-12-07 上海应用技术学院 一种透明质酸修饰的脂质介孔硅核壳纳米组装体及其制备方法
JP7510254B2 (ja) 2016-08-10 2024-07-03 ユナイテッド キングダム リサーチ アンド イノベーション ナノシリカ粒子を含む組成物および療法のためにｔリンパ球を活性化する方法におけるそれらの使用
CN106265432A (zh) 2016-08-30 2017-01-04 钟治超 一种含有薄荷精油的美白美容乳剂
LU100023B1 (en) 2017-01-20 2018-07-30 Luxembourg Inst Science & Tech List Nanocapsules and method for manufacturing thereof
CN106806343B (zh) 2017-02-17 2020-10-13 清华大学深圳研究生院 一种叶酸和聚多巴胺修饰的肿瘤靶向介孔二氧化硅纳米粒及制备方法与应用
US20200261580A1 (en) 2017-07-17 2020-08-20 Andrea Willey Photodynamic Therapy Method for Skin Disorders
US20200375912A1 (en) 2017-08-03 2020-12-03 Rita Elena Serda Liposomal coated nanoparticles for immunotherapy applications
CN107625966A (zh) 2017-09-10 2018-01-26 河南工业大学 一种自组装式脂质‑介孔硅核/壳复合型纳米药物载体及其制备方法
CN107616952A (zh) 2017-10-31 2018-01-23 广州赛莱拉干细胞科技股份有限公司 一种含菊花细胞提取物的祛皱护肤组合物及其制备方法
CN107998264A (zh) 2018-01-15 2018-05-08 福建傲农生物科技集团股份有限公司 一种治疗猪呼吸道疾病的中西药复方超微粉剂及其制备方法与应用
CN108552223A (zh) 2018-01-17 2018-09-21 天津市植物保护研究所 一种含芽胞杆菌的液体菌悬剂及其应用

Also Published As

Publication number Publication date
US20260096997A1 (en) 2026-04-09
CN113677332B (zh) 2023-11-03
AU2020249810B2 (en) 2024-12-19
JP2024169482A (ja) 2024-12-05
JP2022529579A (ja) 2022-06-23
AU2020249810A1 (en) 2021-11-11
EP3946280A1 (en) 2022-02-09
US20230052784A1 (en) 2023-02-16
CN117398362A (zh) 2024-01-16
US12496278B2 (en) 2025-12-16
JP7784754B2 (ja) 2025-12-12
CA3133117C (en) 2024-04-02
JP7637416B2 (ja) 2025-02-28
CN113677332A (zh) 2021-11-19
WO2020193999A1 (en) 2020-10-01
CA3133117A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
GB201904337D0 (en) A delivery system
GB201907302D0 (en) Delivery system
PL3693325T3 (pl) System dostawczy
GB202012051D0 (en) Delivery systems
PL4064914T3 (pl) Układ dostarczania aerozolu
GB202004701D0 (en) Delivery system
PL4076109T3 (pl) System zapewniania przepływu
GB201904336D0 (en) A delivery system
GB202008130D0 (en) Delivery system
GB201916884D0 (en) Nanoparticle-like delivery system
GB202008120D0 (en) Delivery system
PL3834639T3 (pl) Układ dostarczający aerozol
IL313377A (en) Delivery system
IL271708A (en) One-wheel vehicle system
GB202004702D0 (en) Delivery system
GB202004731D0 (en) Delivery system
GB202004730D0 (en) Delivery system
GB202004707D0 (en) Delivery system
GB201912834D0 (en) Aerosol delivery system
GB201820575D0 (en) A system
GB201813406D0 (en) A system
GB201915750D0 (en) A computering system
IL313381A (en) transfer system
GB202113045D0 (en) Delivery System
GB202110546D0 (en) Delivery system

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)